Loading...
MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a...
Na minha lista:
| Udgivet i: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6906491/ https://ncbi.nlm.nih.gov/pubmed/31827134 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55208-5 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|